Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Adrian F. Ochsenbein, Rolf A. Stahel et al.|Clinical Lung Cancer|2015Cited by 15
PUB041 HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09)Sacha I. Rothschild, Rolf Jaggi, Oliver Gautschi et al.|Journal of Thoracic Oncology|2017Cited by 0